Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells.

Carpino N, Wisniewski D, Strife A, Marshak D, Kobayashi R, Stillman B, Clarkson B.

Cell. 1997 Jan 24;88(2):197-204.

2.

Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins.

Di Cristofano A, Carpino N, Dunant N, Friedland G, Kobayashi R, Strife A, Wisniewski D, Clarkson B, Pandolfi PP, Resh MD.

J Biol Chem. 1998 Feb 27;273(9):4827-30.

4.

Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.

Bhat A, Johnson KJ, Oda T, Corbin AS, Druker BJ.

J Biol Chem. 1998 Nov 27;273(48):32360-8.

5.

Tyrosine phosphorylated proteins in chronic myelogenous leukemia.

Frackelton AR Jr, Kumar PS, Kannan B, Clark JW.

Leuk Lymphoma. 1993;11 Suppl 1:125-9.

PMID:
7504542
7.

Tyrosine phosphorylation of p62dok by p210bcr-abl inhibits RasGAP activity.

Kashige N, Carpino N, Kobayashi R.

Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2093-8. Erratum in: Proc Natl Acad Sci U S A 2000 May 23;97(11):6236.

8.

Phosphatidylinositol 3-kinase and Src family kinases are required for phosphorylation and membrane recruitment of Dok-1 in c-Kit signaling.

Liang X, Wisniewski D, Strife A, Shivakrupa, Clarkson B, Resh MD.

J Biol Chem. 2002 Apr 19;277(16):13732-8. Epub 2002 Feb 1.

9.

p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl).

Di Cristofano A, Niki M, Zhao M, Karnell FG, Clarkson B, Pear WS, Van Aelst L, Pandolfi PP.

J Exp Med. 2001 Aug 6;194(3):275-84.

10.
12.

Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.

Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW.

Blood. 1994 Nov 1;84(9):2912-8.

13.

p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.

Salgia R, Pisick E, Sattler M, Li JL, Uemura N, Wong WK, Burky SA, Hirai H, Chen LB, Griffin JD.

J Biol Chem. 1996 Oct 11;271(41):25198-203.

14.

SHP-1 regulation of p62(DOK) tyrosine phosphorylation in macrophages.

Berg KL, Siminovitch KA, Stanley ER.

J Biol Chem. 1999 Dec 10;274(50):35855-65.

15.

Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.

Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD.

Exp Hematol. 1993 Oct;21(11):1460-6.

PMID:
8405226
18.

New understanding of the pathogenesis of CML: a prototype of early neoplasia.

Clarkson BD, Strife A, Wisniewski D, Lambek C, Carpino N.

Leukemia. 1997 Sep;11(9):1404-28. Review.

PMID:
9305592
19.

Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia.

Yasuda T, Shirakata M, Iwama A, Ishii A, Ebihara Y, Osawa M, Honda K, Shinohara H, Sudo K, Tsuji K, Nakauchi H, Iwakura Y, Hirai H, Oda H, Yamamoto T, Yamanashi Y.

J Exp Med. 2004 Dec 20;200(12):1681-7.

20.

Mediation by the protein-tyrosine kinase Tec of signaling between the B cell antigen receptor and Dok-1.

Yoshida K, Yamashita Y, Miyazato A, Ohya K, Kitanaka A, Ikeda U, Shimada K, Yamanaka T, Ozawa K, Mano H.

J Biol Chem. 2000 Aug 11;275(32):24945-52.

Supplemental Content

Support Center